ישראל - עברית - Ministry of Health

j-c health care ltd - infliximab - אבקה להכנת תרכיז לאינפוזיה - infliximab 100.0 mg/vial - infliximab - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

ישראל - עברית - Ministry of Health

novartis israel ltd - basiliximab - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - basiliximab 20 mg/vial - basiliximab - basiliximab - prophylaxis of acute organ rejection in de novo renal transplantation in combination with cyclosporin and corticosteroid based immunosuppression

ישראל - עברית - Ministry of Health

novartis israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

ישראל - עברית - Ministry of Health

neopharm (israel) 1996 ltd - maralixibat chloride - תמיסה (פומי) - maralixibat chloride 10 mg/ml - maralixibat chloride

ישראל - עברית - Ministry of Health

neopharm (israel)1996 ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg / 1 ml - adalimumab

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg/ml - adalimumab

ישראל - עברית - Ministry of Health

amgen europe b.v. - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - infliximab - אבקה להכנת תמיסה מרוכזת לעירוי - infliximab 100 mg - infliximab